STUDY TO EVALUATE THE EFFECT OF AGE AND RENAL FUNCTION OF OCTREOSCAN

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。生长抑素是一种14个氨基酸的肽激素，在内分泌稳态中具有多种功能，包括抑制生长激素的释放，抑制胰高血糖素和胰岛素的分泌。它在脑组织、胃肠道和胰腺中含量很高。多种肿瘤表达生长抑素受体及其类似物；这些受体的流行在不同的肿瘤类型中有所不同。神经内分泌类肿瘤显示出生长抑素受体的高患病率。奥曲肽是一种合成的生长抑素类似物，旨在克服生长抑素循环半衰期短（2-4分钟）的缺点。OctreoScan （in -111戊曲肽）是一种放射性标记的奥曲肽类似物，已在美国和欧洲获得批准，用于携带生长抑素受体的原发性和转移性神经内分泌肿瘤的科学定位。本研究专门评估了年龄（老年）和肾功能对octrescan在推荐临床剂量下的安全性、有效性和药代动力学特征的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Somatostatin is a 14-amino-acid peptide hormone that has many functions in endocrine homeostasis, including inhibiting the release of growth hormone and suppressing glucagon and insulin secretion. It is found in high concentrations in brain tissue, the gastrointestinal tract, and the pancreas. A variety of tumors express receptors for somatostatin and its analogs; the prevalence of these receptors varies among different tumor types. The neuroendocrine class of tumors demonstrates a high prevalence of somatostatin receptors. Octreotide is a synthetic analog of somatostatin developed to overcome the short circulating half-life of somatostatin (2-4 minutes). OctreoScan (indium In-111 pentetreotide) is a radiolabeled analog of octreotide approved in the United States and Europe for the scintigraphic localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors. This study specifically addresses the evaluation of the effect of age (geriatric) and renal function on the safety, efficacy and pharmacokinetic profiles of OctreoScan in this patient population at the recommended clinical dose.